New targeted drug shows promise for Hard-to-Treat cancers
Disease control
Completed
This study tested a new drug called LM-302 in 153 people with advanced solid tumors that have a specific protein called CLDN18.2. The drug is designed to target and kill cancer cells while sparing healthy ones. The main goals were to check safety, find the right dose, and see ear…
Phase: PHASE1, PHASE2 • Sponsor: LaNova Medicines Zhejiang Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 16:40 UTC